SynthesisBMC medical genomics2014
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes.
Synthesis in BMC medical genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Construction and validation of a chromatin regulator-related gene signature for prognostic and therapeutic significance of clear cell renal cell carcinoma.Translational cancer research · 2024Article
- Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nature genetics · 2023Article
- Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer.International journal of molecular sciences · 2022Article
- GANAB andInternational journal of molecular sciences · 2022Review
- Article
- A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.Saudi journal of biological sciences · 2022Review
- RFC4 promotes the progression and growth of Oral Tongue squamous cell carcinoma in vivo and vitro.Journal of clinical laboratory analysis · 2021Article
- Screening of cervical cancer-related hub genes based on comprehensive bioinformatics analysis.Cancer biomarkers : section A of Disease markers · 2021Article
- The expression and prognostic value of GLYATL1 and its potential role in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2020Article
- Article
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- Article
- Multifaceted regulation and functions of replication factor C family in human cancers.American journal of cancer research · 2018Review
- Towards integrated oncogenic marker recognition through mutual information-based statistically significant feature extraction: an association rule mining based study on cancer expression and methylation profiles.Quantitative biology (Beijing, China) · 2017Article
- Microarray analyses reveal genes related to progression and prognosis of esophageal squamous cell carcinoma.Oncotarget · 2017Article
- Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer.Oncology letters · 2017Article
- c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.EBioMedicine · 2017Article
- ERG expression in prostate cancer: biological relevance and clinical implication.Journal of cancer research and clinical oncology · 2016Review
- The role of glycans in the development and progression of prostate cancer.Nature reviews. Urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundTumorigenesis is characterised by changes in transcriptional control. Extensive transcript expression data have been acquired over the last decade and used to classify prostate cancers. Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in identifying robust transcript biomarkers.
methodsIn this study, we have undertaken a meta-analysis of publicly available transcriptomic data spanning datasets and technologies from the last decade and encompassing laser capture microdissected and macrodissected sample sets.
resultsWe identified a 33 gene signature that can discriminate between benign tissue controls and localised prostate cancers irrespective of detection platform or dissection status. These genes were significantly overexpressed in localised prostate cancer versus benign tissue in at least three datasets within the Oncomine Compendium of Expression Array Data. In addition, they were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, glycosylation was the single enriched process associated with this 33 gene signature, encompassing four glycosylating enzymes. We went on to evaluate the performance of this signature against three individual markers of prostate cancer, v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression and androgen receptor (AR) expression in an additional independent dataset. Our signature had greater discriminatory power than these markers both for localised cancer and metastatic disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer.
conclusionIn conclusion, robust transcript biomarkers are present within datasets assembled over many years and cohorts and our study provides both examples and a strategy for refining and comparing datasets to obtain additional markers as more data are generated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.